The direct, indirect, and intangible costs due to neovascular age-related macular degeneration, diabetic macular edema, and proliferative diabetic retinopathy is estimated to cost the U.S. approximately $21 billion by 2020, according to a speaker at the Retina World Congress in Fort Lauderdale, Florida, Healio.com reports.
“Age-related macular degeneration will constitute the lion’s share of this amount with a little over $16 billion. Diabetic retinopathy will be about $4.5 billion,” Andrew A. Moshfeghi said at the meeting.
Dr. Moshfeghi said that if management of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR) did not improve, the costs associated with these diseases could triple by 2050.
Read the full story: